In contrast, continued expression of PD-L1 in GVHD target parenchymal tissues triggers PD-1 signaling in the STAT3–/– T cells to downregulate GSH/Myc pathways, leading to impaired metabolic reprogramming, T cell dysfunction, and GVHD prevention. The gene discussed is MYC; the disease is graft versus host disease.